What the conservative pathway actually means

The question most people bring to their GP is 'do I need a hip replacement?' — but for the majority of adults with hip osteoarthritis, that question arrives too early. Before surgery enters the picture, UK clinical guidance is unambiguous: a structured programme of non-surgical care must be tried and documented first.

NICE NG226, published in October 2022, sets the standard. For anyone aged 45 or over with activity-related hip pain and morning stiffness lasting no longer than 30 minutes, a clinical diagnosis is sufficient to begin treatment — no X-ray or MRI is required at the outset. It removes a common reason for delay and shifts focus to starting treatment early rather than waiting for scan results.

NHS commissioning pathways put this into practice locally. North Yorkshire CCG and Devon's formulary pathway both require documented completion of conservative measures — physiotherapy, analgesia, weight management, and lifestyle modification — before a total hip replacement (THR) referral is accepted. Referrals that arrive without this evidence may be returned.

The pathway is a layered sequence, not a single intervention. Exercise and education sit at its core; weight management is added for those who are overweight; analgesia and injection therapy follow where needed. Imaging is not the primary driver: radiographic severity correlates poorly with reported pain, so scan findings alone do not determine when — or whether — surgery becomes appropriate. Quality-of-life impact does.

Exercise and physiotherapy as the foundation

Therapeutic exercise sits at the top of every major guideline's recommendation list — not as a general lifestyle suggestion, but as a mandated component of care for all hip OA patients, regardless of how severe symptoms are. NICE NG226 and OARSI both identify it as a core intervention, and Bennell's 2013 review confirmed that exercise and education should be offered universally, with weight management added for those who are overweight.

In practice, a physiotherapy programme begins with gentle range-of-motion work to restore mobility across the joint, then progresses to strengthening — principally the gluteal and core muscles, which stabilise the hip and reduce load on the articular surface. An MSK physiotherapist designs and adjusts this progression based on the individual's pain levels, fitness, and day-to-day function; there is no single fixed protocol.

Aerobic activity is encouraged throughout. Low-impact modalities such as cycling and swimming are preferred over running or high-impact sport because they maintain joint mobility and cardiovascular fitness while keeping forces through the hip manageable.

Education about the condition is itself a prescribed element, not a supplement to the physical work. Patients who understand what osteoarthritis is and how it typically behaves — that symptoms may fluctuate rather than steadily worsen — are better placed to engage consistently with their exercise programme, which is where most of the treatment benefit accumulates.

The research base for exercise specifically in hip OA is thinner than for knee OA; most large randomised controlled trials have targeted the knee. Even so, international guidelines are consistent: therapeutic exercise remains the single best-supported non-surgical treatment for hip osteoarthritis.

Activity modification and weight management

Reducing activity is a common instinct when a joint is painful — but for hip OA, inactivity tends to worsen rather than relieve symptoms over time. The more useful adjustment is switching high-impact activities such as running, jumping, or contact sport for lower-impact alternatives that keep the joint moving without repeatedly provoking it.

For patients who are overweight, weight management is a mandated core intervention — not a lifestyle footnote. Each additional kilogram of body weight increases load through a weight-bearing joint; reducing that load is mechanically meaningful and may ease symptoms independently of other treatments. NICE NG226 includes weight management alongside exercise and education as a standard component of care for eligible patients.

Assistive devices offer a practical complement to these changes. A walking cane, held in the hand opposite the affected hip, can reduce joint loading during daily activity and may take the edge off pain during flares. Shoe inserts are also used by some patients, though evidence here is less robust.

Taken together, these measures are designed to sustain function and reduce symptom provocation while physiotherapy, analgesia, and injection therapy take effect — they are active management tools, not a plan to avoid using the hip indefinitely.

Medications and injections: what the evidence supports

Pain relief through medication plays a supporting role in the pathway — keeping discomfort manageable enough that exercise and activity remain possible, rather than replacing them.

What the evidence supports

Topical or oral NSAIDs are the best-evidenced pharmacological option for hip OA pain, endorsed consistently across NICE NG226, OARSI, ACR, and EULAR. They work as an adjunct to the exercise programme, not a substitute for it.

Corticosteroid injections into the hip joint can provide meaningful pain relief lasting roughly three to six months and may be repeated approximately every six months. Their most practical role is as a bridge: when pain is severe enough to prevent engagement with physiotherapy, an injection may restore a window in which exercise becomes tolerable again. They do not slow joint deterioration and are not a long-term solution in isolation.

What the guidelines advise against

Glucosamine, opioids, and viscosupplementation (hyaluronic acid injections) are consistently not recommended for hip OA by the same guideline bodies. Evidence for glucosamine and hyaluronic acid in the hip is either weak or absent; opioids carry substantial risk without established benefit for this indication. Patients who encounter these options — through private clinics or peer recommendation — should be aware that current international guidelines do not support their routine use for hip OA.

What remains uncertain

Platelet-rich plasma (PRP) shows early signals of potential benefit, but hip-specific trial data are currently insufficient for any major guideline to recommend it as standard care.

Who guides the decision at each stage

The UK pathway for hip OA involves several clinicians at distinct points, each with a specific role rather than an overlapping one.

The GP is the first port of call — initiating conservative management, co-ordinating analgesia, and making the onward referral once documented evidence of completed conservative measures is in place. An MSK physiotherapist leads the exercise and rehabilitation programme, and is well-placed to identify when a genuine, sustained attempt at conservative care has reached a plateau in benefit — a signal that can inform the GP's referral decision.

Some NHS areas introduce a community musculoskeletal assessment service between primary care and an orthopaedic appointment; the South and West Devon commissioned pathway is one example. This triage layer provides structured holistic evaluation, including the Oxford Hip Score — a 12-question patient-reported measure of pain and function — alongside formal patient decision aids that set out what surgery does and does not reliably achieve. Where no such community service exists, patients move directly to an orthopaedic consultant.

The consultant reviews clinical findings, imaging, and patient-reported outcomes to determine whether a hip is technically suitable for replacement. That clinical determination, however, is only one half of the decision.

The other half belongs to the patient. A surgeon can confirm surgical suitability; only the patient can judge whether their quality of life has deteriorated sufficiently to make the risks of a major procedure worthwhile. Surgery is not scheduled on the basis of an X-ray finding alone — lived impact and personal readiness are the primary drivers of timing.

Where red flags are present — suspected infection, malignancy, fracture, or neurovascular compromise — this graduated pathway is bypassed in favour of urgent secondary care review.

When conservative treatment has run its course

No national guideline sets a countdown on conservative care. NICE NG226 deliberately avoids specifying a minimum treatment duration — the threshold is functional failure: pain and disability significantly affecting daily life despite sustained, genuine engagement with non-surgical measures. That is the clinical signal, not a fixed number of weeks.

Completing the programme has its own value. A hip that has been consistently exercised and weight-managed is better prepared for surgery if that point arrives; equally, a meaningful proportion of patients find symptoms stabilise enough to defer — or avoid — the operating table.

Local commissioning criteria

NHS thresholds for listing a patient for total hip replacement vary across England. Some integrated care boards require specific BMI or smoking-cessation criteria before a patient can be added to a waiting list — criteria that NICE does not set nationally. Patients whose GP considers them approaching referral should ask about local requirements early to avoid avoidable delays.

The listing decision remains shared between patient and consultant. What carries most clinical weight is the patient's own account of daily functional impact — including, where a community assessment has taken place, a documented Oxford Hip Score that puts a number to the trajectory of deterioration.

Finding a specialist

Search MSK is a UK-wide directory of orthopaedic and MSK specialists, searchable by region and clinical focus without preference between providers. Patients researching next steps for hip osteoarthritis — whether approaching NHS referral or exploring independent assessment — can filter by region and specialty to find a consultant suited to their stage.